{"id":10708,"date":"2024-02-27T11:00:00","date_gmt":"2024-02-27T16:00:00","guid":{"rendered":"https:\/\/ibkrcampus.eu\/uncategorized\/the-other-nv-stock\/"},"modified":"2024-02-28T09:41:35","modified_gmt":"2024-02-28T09:41:35","slug":"the-other-nv-stock","status":"publish","type":"post","link":"https:\/\/www.interactivebrokers.eu\/campus\/traders-insight\/securities\/stocks\/the-other-nv-stock\/","title":{"rendered":"The Other “NV*” Stock"},"content":{"rendered":"\n

While it is clear that Nvidia (NVDA) has consumed a significant, though not inordinate, amount of attention recently, there is another stock with a similar symbol that has been a stellar performer with a potentially life-changing product.  That would be Novo Nordisk (NVO, NOVO.B), which had a competitive hiccup today when Viking Therapeutics (VKTX) reported a positive Phase 2 trial for its own obesity drug.<\/p>\n\n\n\n

Although Novo is domiciled in Denmark (the local symbol is NOVO.B), its ADRs (NVO on the NYSE) have a higher average daily volume than the ordinary shares.  That is a testament to the level of interest and enthusiasm for the stock and its key products \u2013 the diabetes and weight loss drugs Ozempic and Wegovy — on a global scale.  Another testament to that enthusiasm is the fact that NVO has roughly doubled in the past year and a half.<\/p>\n\n\n\n

2-Year Chart NOVO.B (daily candles, right scale in DKK), NVO (blue line)<\/em><\/strong><\/h3>\n\n\n\n
\"2-Year<\/figure>\n\n\n\n

Source: Interactive Brokers<\/em><\/p>\n\n\n\n

Past performance is not indicative of future results<\/p>\n\n\n\n

Over that time period, Eli Lilly (LLY), maker of the competing Mounjaro and Zepbound, has had a similar, even more spectacular rise.  That stock also dipped today on the VKTX news:<\/p>\n\n\n\n

2-Year Chart LLY (daily candles, right scale), NVO (blue line)<\/em><\/strong><\/h3>\n\n\n\n
\"2-Year<\/figure>\n\n\n\n

Source: Interactive Brokers<\/em><\/p>\n\n\n\n

Past performance is not indicative of future results<\/p>\n\n\n\n

As a result of the stock\u2019s appreciation, LLY surpassed TSLA\u2019s market capitalization in January, and NVO is not far behind.  In an article from that time, I commented<\/a>:<\/p>\n\n\n\n

\u201cMarkets tend to favor big broad trends and certainly one of those trends at one point was electric vehicles and all things Tesla,\u201d said Steve Sosnick, chief strategist at Interactive Brokers. \u201cRight now, the trends that are really gripping investors are artificial intelligence and GLP1 weight loss drugs.\u201d<\/em><\/p>\n\n\n\n

Considering that we have discussed artificial intelligence<\/a> quite frequently, if not ad nauseum<\/a>, it is appropriate that we devote some time to GLP excitement.<\/p>\n\n\n\n

During the run-ups in both NVO and LLY, there has been a series of news reports analyzing the potential effects of the new GLP1 drugs on both consumer goods companies and health insurers.  Because these drugs suppress appetites, the former set of concerns relates to whether the widespread adoption of GLP1s will depress demand for a caloric foods and beverages.  In theory, these could be a major negative for anyone who makes or sells processed foods.  But the second concern, the one regarding its effect on health insurance companies, mitigates the effect of the former.  These drugs are very costly, at least in the US.  The high demand is forcing insurers to decide whether the potential long-term benefits of reducing obesity and controlling diabetes justify the high monthly costs of the drugs.  For now, many are loath to cover the costs, particularly when the customer is only moderately overweight or if their diabetes can be controlled with cheaper medications. <\/p>\n\n\n\n

The benefit to these companies is that there is no shortage of well-heeled consumers who are willing to pay for the drugs, nonetheless.  Vanity is a powerful motivator.  A doctor friend commented to me that a high percentage of the members of a club that we belong to have inquired about these drugs, and that many willingly hundreds of dollars out of pocket to manage their weight.  A weekly injection is certainly easier to manage than a diet and exercise regimen, and NVO and LLY are reaping the rewards.<\/p>\n\n\n\n

That is why we have only seen a modest dip today in NVO and LLY despite the potential emergence of a new competitor in VKTX.  The news is certainly encouraging for the smaller biotech company, with its stock doubling today, but it is not necessarily discouraging for the drug giants \u2013 at least in the short-term.  For starters, the VKTX drug still needs further approvals from the FDA before it can come to market.  Secondly, at least for now, demand for these drugs is outpacing supply, so a new entrant could simply expand the marketplace in the long run. <\/p>\n\n\n\n

Although it is not obvious from the upward trajectories in the two-year charts above, a shorter-term chart shows that a pause may be occurring.  We might be seeing a bit of a topping pattern at play.  Note the two candles highlighted below.  They show the NVO opening lower but seeing sufficient \u201cbuy-the-dip\u201d activity to close most of the opening downward gaps.  There is clearly demand for the shares from traders, but it is possible that longer-term investors may be taking a bit of a breather.  It is likely premature to be outright bearish on either NVO or LLY \u2013 the long-term upside trends are still too powerful \u2013 but a bit of short-term caution may be warranted in the \u201dother NV stock.\u201d<\/p>\n\n\n\n

NVO, 3-Month Daily Candles<\/em><\/strong><\/h3>\n\n\n\n
\"NVO,<\/figure>\n\n\n\n

Source: Interactive Brokers<\/em><\/p>\n\n\n\n

Past performance is not indicative of future results<\/p>\n","protected":false},"excerpt":{"rendered":"

While it is clear that Nvidia (NVDA) has consumed a significant, though not inordinate, amount of attention recently, there is another stock with a similar symbol that has been a stellar performer with a potentially life-changing product. That would be Novo Nordisk (NVO, NOVO.B).<\/p>\n","protected":false},"author":4,"featured_media":10712,"comment_status":"open","ping_status":"closed","sticky":true,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[147,8,12,153,148,7],"tags":[],"contributors-categories":[149],"class_list":{"0":"post-10708","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-north-america","8":"category-region","9":"category-securities","10":"category-stocks","11":"category-text-articles","12":"category-traders-insight","13":"contributors-categories-interactive-brokers"},"pp_statuses_selecting_workflow":false,"pp_workflow_action":"current","pp_status_selection":"publish","acf":[],"yoast_head":"\nThe Other “NV*” Stock | Traders' Insight<\/title>\n<meta name=\"description\" content=\"While it is clear that Nvidia (NVDA) has consumed a significant amount of attention recently, there is another stock with a similar symbol that has been...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interactivebrokers.com\/campus\/wp-json\/wp\/v2\/posts\/10708\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Other "NV*" Stock\" \/>\n<meta property=\"og:description\" content=\"While it is clear that Nvidia (NVDA) has consumed a significant amount of attention recently, there is another stock with a similar symbol that has been a stellar performer. That would be Novo Nordisk (NVO, NOVO.B).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interactivebrokers.eu\/campus\/traders-insight\/securities\/stocks\/the-other-nv-stock\/\" \/>\n<meta property=\"og:site_name\" content=\"IBKR Campus EU\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-27T16:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-28T09:41:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.interactivebrokers.eu\/campus\/wp-content\/uploads\/sites\/3\/2024\/02\/stocks-financial-instruments-featured-img.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"563\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Steve Sosnick\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Steve Sosnick\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\n\t \"@context\": \"https:\\\/\\\/schema.org\",\n\t \"@graph\": [\n\t {\n\t \"@type\": \"Article\",\n\t \"@id\": \"https:\\\/\\\/www.interactivebrokers.eu\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/the-other-nv-stock\\\/#article\",\n\t \"isPartOf\": {\n\t \"@id\": \"https:\\\/\\\/www.interactivebrokers.eu\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/the-other-nv-stock\\\/\"\n\t },\n\t \"author\": {\n\t \"name\": \"Steve Sosnick\",\n\t \"@id\": \"https:\\\/\\\/ibkrcampus.eu\\\/campus\\\/#\\\/schema\\\/person\\\/31988d9596575a63ddc53e92049a2549\"\n\t },\n\t \"headline\": \"The Other “NV*” Stock\",\n\t \"datePublished\": \"2024-02-27T16:00:00+00:00\",\n\t \"dateModified\": \"2024-02-28T09:41:35+00:00\",\n\t \"mainEntityOfPage\": {\n\t \"@id\": \"https:\\\/\\\/www.interactivebrokers.eu\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/the-other-nv-stock\\\/\"\n\t },\n\t \"wordCount\": 834,\n\t \"commentCount\": 0,\n\t \"image\": {\n\t \"@id\": \"https:\\\/\\\/www.interactivebrokers.eu\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/the-other-nv-stock\\\/#primaryimage\"\n\t },\n\t \"thumbnailUrl\": \"https:\\\/\\\/www.interactivebrokers.eu\\\/campus\\\/wp-content\\\/uploads\\\/sites\\\/3\\\/2024\\\/02\\\/stocks-financial-instruments-featured-img.jpg\",\n\t \"articleSection\": [\n\t \"North America\",\n\t \"Region\",\n\t \"Securities\",\n\t \"Stocks\",\n\t \"Text Articles\",\n\t \"Traders' Insight\"\n\t ],\n\t \"inLanguage\": \"en-US\",\n\t \"potentialAction\": [\n\t {\n\t \"@type\": \"CommentAction\",\n\t \"name\": \"Comment\",\n\t \"target\": [\n\t \"https:\\\/\\\/www.interactivebrokers.eu\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/the-other-nv-stock\\\/#respond\"\n\t ]\n\t }\n\t ]\n\t },\n\t {\n\t \"@type\": \"WebPage\",\n\t \"@id\": \"https:\\\/\\\/www.interactivebrokers.eu\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/the-other-nv-stock\\\/\",\n\t \"url\": \"https:\\\/\\\/www.interactivebrokers.eu\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/the-other-nv-stock\\\/\",\n\t \"name\": \"The Other \\\"NV*\\\" Stock - IBKR Campus EU\",\n\t \"isPartOf\": {\n\t \"@id\": \"https:\\\/\\\/ibkrcampus.eu\\\/campus\\\/#website\"\n\t },\n\t \"primaryImageOfPage\": {\n\t \"@id\": \"https:\\\/\\\/www.interactivebrokers.eu\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/the-other-nv-stock\\\/#primaryimage\"\n\t },\n\t \"image\": {\n\t \"@id\": \"https:\\\/\\\/www.interactivebrokers.eu\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/the-other-nv-stock\\\/#primaryimage\"\n\t },\n\t \"thumbnailUrl\": \"https:\\\/\\\/www.interactivebrokers.eu\\\/campus\\\/wp-content\\\/uploads\\\/sites\\\/3\\\/2024\\\/02\\\/stocks-financial-instruments-featured-img.jpg\",\n\t \"datePublished\": \"2024-02-27T16:00:00+00:00\",\n\t \"dateModified\": \"2024-02-28T09:41:35+00:00\",\n\t \"author\": {\n\t \"@id\": \"https:\\\/\\\/ibkrcampus.eu\\\/campus\\\/#\\\/schema\\\/person\\\/31988d9596575a63ddc53e92049a2549\"\n\t },\n\t \"description\": \"While it is clear that Nvidia (NVDA) has consumed a significant amount of attention recently, there is another stock with a similar symbol that has been a stellar performer. That would be Novo Nordisk (NVO, NOVO.B).\",\n\t \"breadcrumb\": {\n\t \"@id\": \"https:\\\/\\\/www.interactivebrokers.eu\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/the-other-nv-stock\\\/#breadcrumb\"\n\t },\n\t \"inLanguage\": \"en-US\",\n\t \"potentialAction\": [\n\t {\n\t \"@type\": \"ReadAction\",\n\t \"target\": [\n\t \"https:\\\/\\\/www.interactivebrokers.eu\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/the-other-nv-stock\\\/\"\n\t ]\n\t }\n\t ]\n\t },\n\t {\n\t \"@type\": \"ImageObject\",\n\t \"inLanguage\": \"en-US\",\n\t \"@id\": \"https:\\\/\\\/www.interactivebrokers.eu\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/the-other-nv-stock\\\/#primaryimage\",\n\t \"url\": \"https:\\\/\\\/www.interactivebrokers.eu\\\/campus\\\/wp-content\\\/uploads\\\/sites\\\/3\\\/2024\\\/02\\\/stocks-financial-instruments-featured-img.jpg\",\n\t \"contentUrl\": \"https:\\\/\\\/www.interactivebrokers.eu\\\/campus\\\/wp-content\\\/uploads\\\/sites\\\/3\\\/2024\\\/02\\\/stocks-financial-instruments-featured-img.jpg\",\n\t \"width\": 1000,\n\t \"height\": 563,\n\t \"caption\": \"stocks-financial-instruments-featured-img\"\n\t },\n\t {\n\t \"@type\": \"BreadcrumbList\",\n\t \"@id\": \"https:\\\/\\\/www.interactivebrokers.eu\\\/campus\\\/traders-insight\\\/securities\\\/stocks\\\/the-other-nv-stock\\\/#breadcrumb\",\n\t \"itemListElement\": [\n\t {\n\t \"@type\": \"ListItem\",\n\t \"position\": 1,\n\t \"name\": \"Home\",\n\t \"item\": \"https:\\\/\\\/www.interactivebrokers.eu\\\/campus\\\/\"\n\t },\n\t {\n\t \"@type\": \"ListItem\",\n\t \"position\": 2,\n\t \"name\": \"The Other “NV*” Stock\"\n\t }\n\t ]\n\t },\n\t {\n\t \"@type\": \"WebSite\",\n\t \"@id\": \"https:\\\/\\\/ibkrcampus.eu\\\/campus\\\/#website\",\n\t \"url\": \"https:\\\/\\\/ibkrcampus.eu\\\/campus\\\/\",\n\t \"name\": \"IBKR Campus EU\",\n\t \"description\": \"\",\n\t \"potentialAction\": [\n\t {\n\t \"@type\": \"SearchAction\",\n\t \"target\": {\n\t \"@type\": \"EntryPoint\",\n\t \"urlTemplate\": \"https:\\\/\\\/ibkrcampus.eu\\\/campus\\\/?s={search_term_string}\"\n\t },\n\t \"query-input\": {\n\t \"@type\": \"PropertyValueSpecification\",\n\t \"valueRequired\": true,\n\t \"valueName\": \"search_term_string\"\n\t }\n\t }\n\t ],\n\t \"inLanguage\": \"en-US\"\n\t },\n\t {\n\t \"@type\": \"Person\",\n\t \"@id\": \"https:\\\/\\\/ibkrcampus.eu\\\/campus\\\/#\\\/schema\\\/person\\\/31988d9596575a63ddc53e92049a2549\",\n\t \"name\": \"Steve Sosnick\",\n\t \"description\": \"Steve is the Chief Strategist at Interactive Brokers. He has held numerous roles in the organization since joining Timber Hill, IBKR\u2019s predecessor, in 1995 as Equity Risk Manager and an options market maker. He developed and implemented automated trading strategies for stocks and options before moving into his current role. Steve has guest authored several columns in Barron\u2019s and made numerous live on Bloomberg TV and Radio, CNBC, Yahoo Finance, Fox Business, and several other media outlets several media outlets in North America, Asia, Australia, and the Middle East in addition to being quoted frequently in print and electronic media. Prior to joining Interactive Brokers, Sosnick held senior trading roles at Morgan Stanley, Lehman Brothers, and Salomon Brothers, where he completed the firm\u2019s famed training program.\",\n\t \"sameAs\": [\n\t \"https:\\\/\\\/ibkr.com\"\n\t ],\n\t \"url\": \"https:\\\/\\\/www.interactivebrokers.eu\\\/campus\\\/author\\\/steve-sosnick\\\/\"\n\t }\n\t ]\n\t}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The Other “NV*” Stock | Traders' Insight","description":"While it is clear that Nvidia (NVDA) has consumed a significant amount of attention recently, there is another stock with a similar symbol that has been...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interactivebrokers.com\/campus\/wp-json\/wp\/v2\/posts\/10708\/","og_locale":"en_US","og_type":"article","og_title":"The Other \"NV*\" Stock","og_description":"While it is clear that Nvidia (NVDA) has consumed a significant amount of attention recently, there is another stock with a similar symbol that has been a stellar performer. That would be Novo Nordisk (NVO, NOVO.B).","og_url":"https:\/\/www.interactivebrokers.eu\/campus\/traders-insight\/securities\/stocks\/the-other-nv-stock\/","og_site_name":"IBKR Campus EU","article_published_time":"2024-02-27T16:00:00+00:00","article_modified_time":"2024-02-28T09:41:35+00:00","og_image":[{"width":1000,"height":563,"url":"https:\/\/www.interactivebrokers.eu\/campus\/wp-content\/uploads\/sites\/3\/2024\/02\/stocks-financial-instruments-featured-img.jpg","type":"image\/jpeg"}],"author":"Steve Sosnick","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Steve Sosnick","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.interactivebrokers.eu\/campus\/traders-insight\/securities\/stocks\/the-other-nv-stock\/#article","isPartOf":{"@id":"https:\/\/www.interactivebrokers.eu\/campus\/traders-insight\/securities\/stocks\/the-other-nv-stock\/"},"author":{"name":"Steve Sosnick","@id":"https:\/\/ibkrcampus.eu\/campus\/#\/schema\/person\/31988d9596575a63ddc53e92049a2549"},"headline":"The Other “NV*” Stock","datePublished":"2024-02-27T16:00:00+00:00","dateModified":"2024-02-28T09:41:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.interactivebrokers.eu\/campus\/traders-insight\/securities\/stocks\/the-other-nv-stock\/"},"wordCount":834,"commentCount":0,"image":{"@id":"https:\/\/www.interactivebrokers.eu\/campus\/traders-insight\/securities\/stocks\/the-other-nv-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interactivebrokers.eu\/campus\/wp-content\/uploads\/sites\/3\/2024\/02\/stocks-financial-instruments-featured-img.jpg","articleSection":["North America","Region","Securities","Stocks","Text Articles","Traders' Insight"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.interactivebrokers.eu\/campus\/traders-insight\/securities\/stocks\/the-other-nv-stock\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.interactivebrokers.eu\/campus\/traders-insight\/securities\/stocks\/the-other-nv-stock\/","url":"https:\/\/www.interactivebrokers.eu\/campus\/traders-insight\/securities\/stocks\/the-other-nv-stock\/","name":"The Other \"NV*\" Stock - IBKR Campus EU","isPartOf":{"@id":"https:\/\/ibkrcampus.eu\/campus\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.interactivebrokers.eu\/campus\/traders-insight\/securities\/stocks\/the-other-nv-stock\/#primaryimage"},"image":{"@id":"https:\/\/www.interactivebrokers.eu\/campus\/traders-insight\/securities\/stocks\/the-other-nv-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interactivebrokers.eu\/campus\/wp-content\/uploads\/sites\/3\/2024\/02\/stocks-financial-instruments-featured-img.jpg","datePublished":"2024-02-27T16:00:00+00:00","dateModified":"2024-02-28T09:41:35+00:00","author":{"@id":"https:\/\/ibkrcampus.eu\/campus\/#\/schema\/person\/31988d9596575a63ddc53e92049a2549"},"description":"While it is clear that Nvidia (NVDA) has consumed a significant amount of attention recently, there is another stock with a similar symbol that has been a stellar performer. That would be Novo Nordisk (NVO, NOVO.B).","breadcrumb":{"@id":"https:\/\/www.interactivebrokers.eu\/campus\/traders-insight\/securities\/stocks\/the-other-nv-stock\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interactivebrokers.eu\/campus\/traders-insight\/securities\/stocks\/the-other-nv-stock\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.interactivebrokers.eu\/campus\/traders-insight\/securities\/stocks\/the-other-nv-stock\/#primaryimage","url":"https:\/\/www.interactivebrokers.eu\/campus\/wp-content\/uploads\/sites\/3\/2024\/02\/stocks-financial-instruments-featured-img.jpg","contentUrl":"https:\/\/www.interactivebrokers.eu\/campus\/wp-content\/uploads\/sites\/3\/2024\/02\/stocks-financial-instruments-featured-img.jpg","width":1000,"height":563,"caption":"stocks-financial-instruments-featured-img"},{"@type":"BreadcrumbList","@id":"https:\/\/www.interactivebrokers.eu\/campus\/traders-insight\/securities\/stocks\/the-other-nv-stock\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.interactivebrokers.eu\/campus\/"},{"@type":"ListItem","position":2,"name":"The Other “NV*” Stock"}]},{"@type":"WebSite","@id":"https:\/\/ibkrcampus.eu\/campus\/#website","url":"https:\/\/ibkrcampus.eu\/campus\/","name":"IBKR Campus EU","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibkrcampus.eu\/campus\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ibkrcampus.eu\/campus\/#\/schema\/person\/31988d9596575a63ddc53e92049a2549","name":"Steve Sosnick","description":"Steve is the Chief Strategist at Interactive Brokers. He has held numerous roles in the organization since joining Timber Hill, IBKR\u2019s predecessor, in 1995 as Equity Risk Manager and an options market maker. He developed and implemented automated trading strategies for stocks and options before moving into his current role. Steve has guest authored several columns in Barron\u2019s and made numerous live on Bloomberg TV and Radio, CNBC, Yahoo Finance, Fox Business, and several other media outlets several media outlets in North America, Asia, Australia, and the Middle East in addition to being quoted frequently in print and electronic media. Prior to joining Interactive Brokers, Sosnick held senior trading roles at Morgan Stanley, Lehman Brothers, and Salomon Brothers, where he completed the firm\u2019s famed training program.","sameAs":["https:\/\/ibkr.com"],"url":"https:\/\/www.interactivebrokers.eu\/campus\/author\/steve-sosnick\/"}]}},"jetpack_featured_media_url":"https:\/\/www.interactivebrokers.eu\/campus\/wp-content\/uploads\/sites\/3\/2024\/02\/stocks-financial-instruments-featured-img.jpg","_links":{"self":[{"href":"https:\/\/ibkrcampus.eu\/campus\/wp-json\/wp\/v2\/posts\/10708","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibkrcampus.eu\/campus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibkrcampus.eu\/campus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibkrcampus.eu\/campus\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/ibkrcampus.eu\/campus\/wp-json\/wp\/v2\/comments?post=10708"}],"version-history":[{"count":0,"href":"https:\/\/ibkrcampus.eu\/campus\/wp-json\/wp\/v2\/posts\/10708\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibkrcampus.eu\/campus\/wp-json\/wp\/v2\/media\/10712"}],"wp:attachment":[{"href":"https:\/\/ibkrcampus.eu\/campus\/wp-json\/wp\/v2\/media?parent=10708"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibkrcampus.eu\/campus\/wp-json\/wp\/v2\/categories?post=10708"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibkrcampus.eu\/campus\/wp-json\/wp\/v2\/tags?post=10708"},{"taxonomy":"contributors-categories","embeddable":true,"href":"https:\/\/ibkrcampus.eu\/campus\/wp-json\/wp\/v2\/contributors-categories?post=10708"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}